Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,664 across all filing types
Latest filing 2023-02-05 Capital/Financing Update
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Proposed $50 Million Capital Facility 2 pages 250.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 6 February 2023 regarding a proposed $50 million capital facility involving a non-binding agreement for a Standby Equity Purchase Agreement (SEPA) facility. It discusses terms of the capital facility, potential share issuance, and strategic implications for the company. There are no financial statements or detailed financial performance data included, nor is this a report or presentation. The content clearly relates to a financing activity and capital structure update. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is 4775 characters, which is sufficient to contain substantive information about the financing arrangement rather than just a brief notice or report publication announcement.
2023-02-05 English
Notification regarding unquoted securities - AVR 9 pages 32.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Notification of Issue, Conversion or Payment up of Unquoted Equity Securities' and details the issuance of unquoted securities under an employee incentive scheme. It includes specifics such as the number of securities issued, their exercise price, expiry date, and references to ASX listing rules. The document is a formal announcement of the issuance of new securities, not a financial report or management discussion. It does not contain financial statements or earnings data. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes. The document length (8173 characters) and content confirm it is a full announcement rather than a brief notice or a report publication announcement.
2023-02-05 English
Pause in Trading 1 page 111.3KB
Regulatory Filings Classification · 100% confidence The document is a brief market release announcing a temporary pause in trading of the company's securities. It is very short (340 characters) and does not contain any financial data, report content, or detailed information. It is an announcement related to trading status, not a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-02-01 English
Trading Halt 2 pages 614.2KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Anteris Technologies Ltd regarding a trading halt requested pending an announcement about a proposed capital raising. It is a short notice informing the market about the halt and the reason for it, without containing any financial data or detailed report. The content fits the category of a Capital/Financing Update as it relates to a capital raising event and trading halt associated with it.
2023-02-01 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 299.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activity Report for the Period to 31 December 2022' and includes detailed operational highlights, financial performance overview, and a comprehensive Appendix 4C quarterly cash flow statement. The content covers actual financial data such as cash flows from operating, investing, and financing activities, as well as cash balances and payments to related parties. The presence of substantive financial data and analysis for a quarter (Q4 2022) indicates this is a quarterly report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement. The Appendix 4C is a standard Australian Securities Exchange (ASX) quarterly cash flow report, confirming the quarterly nature of the filing. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q4 2022
2023-01-30 English
DurAVR First in Human Study 12 Month Results 3 pages 184.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 16 January 2023, providing detailed 12-month clinical study results for the DurAVR Transcatheter Heart Valve (THV) First-in-Human Study. It includes key performance and safety endpoints, clinical data, and CEO and CMO commentary on the study outcomes. The content focuses on clinical trial results and product performance rather than financial results or regulatory filings. It is not a full financial report, earnings release, or management discussion. The document is a detailed update on clinical study results, which is typical for a capital/financing update or product development announcement. However, since it is an official announcement of study results related to the company's product development and future feasibility studies, it fits best under Capital/Financing Update (CAP) as it relates to company progress and potential impact on valuation and financing. The document length (6003 characters) and detailed content confirm it is not a brief report publication announcement or a regulatory filing. Therefore, the most appropriate classification is CAP with high confidence.
2023-01-15 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.